Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
News headlines Recursion Pharmaceuticals (RXRX) is gaining attention due to positive clinical trial results for its drug REC-4881 and a recent upgrade by JPMorgan. Cathie Wood's ARK Investment also ...
DNA Ginkgo Bioworks Holdings, Inc.
10h Pictures: Kelly Piquet shares clicks featuring Max Verstappen, Penelope Kvyat, and Lily Verstappen from the New Year's Eve get-together Pictures: Kelly Piquet shares clicks featuring Max ...
Valerie is a seasoned writer and editor who has spent her career creating content in the parenting and women's wellness spaces. Before joining Forbes Health, Valerie was the trending news editor at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback